A joint appointment at CSHL and Northwell

“We are pleased to announce that Robert D. Maki, M.D., Ph.D., will lead the joint CSHL-Northwell Health Cancer Institute initiative to establish a Cancer Clinical Research Center that will translate the outstanding basic science at CSHL into the clinic,” said Bruce Stillman, President of CSHL. “He is an internationally renowned sarcoma cancer physician and researcher who will work closely with oncologists at Northwell and scientists at CSHL to advance cancer treatment.” Maki is a CSHL professor, member of CSHL’s NCI-designated Cancer Center and the director of the Center for New Cancer Therapies at the Northwell Health Cancer Center. He will play a key role in the strategic affiliation between Northwell and CSHL, established in 2015 to accelerate cancer research, diagnosis and treatment. Maki’s position as director includes building a portfolio of clinical research and exploring unique therapeutics for all cancers, which will increase cutting-edge treatment options for patients throughout the healthcare system.

Childhood cancer community unites at the Lab

Together with the Coalition Against Childhood Cancer (CAC2), CSHL hosted the first ever “From Bench to Bedside and Beyond” conference convening a wide range of childhood cancer community stakeholders at CSHL to advance research. Bruce Stillman opened the 2-day program, followed by presentations from CSHL Associate Professors Chris Vakoc and Mickey Atwal, speakers from the National Cancer Institute, the nation’s top cancer basic and comprehensive cancer centers, and the pharmaceutical industry. They addressed the latest technologies, the clinical pipeline, clinical trials and today’s more promising therapeutics. CSHL proudly joined this effort also supported by sponsors Alex’s Lemonade Stand Foundation, Bristol-Myers Squibb, United Therapeutics and Amgen. Serving a bridging role for childhood cancer stakeholders across the nation, CAC2 has over 90 member organizations and more than 50 individual and student members.

A joint appointment at CSHL and Northwell

“We are pleased to announce that Robert D. Maki, M.D., Ph.D., will lead the joint CSHL-Northwell Health Cancer Institute initiative to establish a Cancer Clinical Research Center that will translate the outstanding basic science at CSHL into the clinic,” said Bruce Stillman, President of CSHL. “He is an internationally renowned sarcoma cancer physician and researcher who will work closely with oncologists at Northwell and scientists at CSHL to advance cancer treatment.” Maki is a CSHL professor, member of CSHL’s NCI-designated Cancer Center and the director of the Center for New Cancer Therapies at the Northwell Health Cancer Center. He will play a key role in the strategic affiliation between Northwell and CSHL, established in 2015 to accelerate cancer research, diagnosis and treatment. Maki’s position as director includes building a portfolio of clinical research and exploring unique therapeutics for all cancers, which will increase cutting-edge treatment options for patients throughout the healthcare system.

A joint appointment at CSHL and Northwell

“We are pleased to announce that Robert D. Maki, M.D., Ph.D., will lead the joint CSHL-Northwell Health Cancer Institute initiative to establish a Cancer Clinical Research Center that will translate the outstanding basic science at CSHL into the clinic,” said Bruce Stillman, President of CSHL. “He is an internationally renowned sarcoma cancer physician and researcher who will work closely with oncologists at Northwell and scientists at CSHL to advance cancer treatment.” Maki is a CSHL professor, member of CSHL’s NCI-designated Cancer Center and the director of the Center for New Cancer Therapies at the Northwell Health Cancer Center. He will play a key role in the strategic affiliation between Northwell and CSHL, established in 2015 to accelerate cancer research, diagnosis and treatment. Maki’s position as director includes building a portfolio of clinical research and exploring unique therapeutics for all cancers, which will increase cutting-edge treatment options for patients throughout the healthcare system.